Communiqués Tectonic Therapeutic, Inc.

Actions

TECX

US8789721086

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 02/10/2026			Varia. 5j.	Varia. 1 janv.
22,54 ^USD	-0,57%		-4,77%	+8,05%

29/09	Tectonic Therapeutic, Inc. annonce des résultats favorables de phase 1 en matière de sécurité, de tolérance et de pharmacocinétique pour TX2100	CI
29/09	Tectonic Therapeutic indique que l’étude de phase 1a de TX2100 a atteint ses objectifs principaux	MT

Communiqués

29/09	Tectonic Therapeutic Announces Favorable Phase 1 Safety, Tolerability and PK Results for TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)	GL
03/09	Tectonic Therapeutic to Participate in the Morgan Stanley Global Healthcare Conference	GL
07/08	Tectonic Therapeutic : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
06/08	Tectonic Therapeutic Announces Second Quarter 2026 Financial Results and Recent Business Highlights	GL
10/06	Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients	GL
08/05	Tectonic Therapeutic : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
07/05	Tectonic Therapeutic Announces First Quarter 2026 Financial Results and Recent Business Highlights	GL
23/04	Tectonic Therapeutic Appoints Jessica Chutter to Board of Directors	GL
02/03	Tectonic Therapeutic to Participate in March Investor Conferences	GL
02/03	Tectonic Therapeutic to Participate in March Investor Conferences	AQ
26/02	Tectonic Therapeutic Announces Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights	GL
23/02	Tectonic Therapeutic Appoints François Nader, M.D., as Chair and Independent Director of the Board	GL
11/02	Tectonic Therapeutic to Host Virtual KOL Event and Discussion of TX2100, a Novel Approach for the Treatment of Hereditary Hemorrhagic Telangiectasia, on February 24, 2026	GL
01/12	Tectonic Therapeutic to Participate in December Investor Conferences	GL
06/11	Tectonic Therapeutic Announces Third Quarter 2025 Financial Results and Recent Business Highlights	GL
29/10/25	Tectonic Therapeutic Announces Positive Topline Data from Phase 1b Part B Clinical Trial for TX45 in Patients with Group 2 Pulmonary Hypertension in HFrEF	GL
28/08/25	Tectonic Therapeutic to Participate in September Investor Conferences	GL
28/08/25	Tectonic Therapeutic to Participate in September Investor Conferences	AQ
07/08/25	Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights	GL
07/08/25	Tectonic Therapeutic Announces Second Quarter 2025 Financial Results and Recent Business Highlights	AQ
30/06/25	Tectonic Therapeutic Joins Russell 3000® Index	GL
19/05/25	Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025	AQ
17/05/25	Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025	AQ
17/05/25	Tectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in Patients with Group 2 Pulmonary Hypertension in HFpEF in Late-Breaking Presentation at ESC Heart Failure 2025	GL
08/05/25	Tectonic Therapeutic Announces First Quarter 2025 Financial Results and Recent Business Highlights	GL